[{"NetIncomeLoss_1_Q2_USD":-15636000.0,"StockholdersEquityNoteStockSplitConversionRatio1_2_Q2_pure":1.0,"NetIncomeLossAttributableToNoncontrollingInterest_2_Q2_USD":686000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q2_USD":-803000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":9982000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":4826000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":42713059.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":43295372.0,"CommitmentsAndContingencies_0_Q2_USD":null,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2_Q2_USD":686000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q2_USD":-803000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":4233000.0,"RoyaltyExpense_2_Q2_USD":0.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-115000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-292320000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":139000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":312850000.0,"AssetsCurrent_0_Q2_USD":344467000.0,"OperatingLeaseExpense_2_Q2_USD":300000.0,"OperatingLeaseExpense_1_Q2_USD":200000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":7131156.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":4165000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-55000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":617856000.0,"Liabilities_0_Q2_USD":5813000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":123670000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":672000.0,"ShortTermInvestments_0_Q2_USD":213035000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":300299000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":24193000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":11778000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":1839447000.0,"MinorityInterest_0_Q2_USD":2991000.0,"AccruedBonusesCurrent_0_Q2_USD":1110000.0,"PrepaidExpenseCurrent_0_Q2_USD":7762000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-10000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-8000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"CommonStockValue_0_Q2_USD":4000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":28000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":265503000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":70932000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-15819000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-15691000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-6495000.0,"OtherAssetsNoncurrent_0_Q2_USD":147000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":564705000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":-16494000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":-113000.0,"CommonStockSharesIssued_0_Q2_shares":43526224.0,"ProceedsFromPaymentsToMinorityShareholders_2_Q2_USD":923000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":332787000.0,"LongTermInvestments_0_Q2_USD":119637000.0,"DeferredRentCreditNoncurrent_0_Q2_USD":70000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-109045000.0,"CommonStockSharesOutstanding_0_Q2_shares":43526224.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":363252000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":24000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-17711000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":608442000.0,"LiabilitiesCurrent_0_Q2_USD":5743000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":-44528000.0,"AccountsPayableCurrent_0_Q2_USD":1510000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":5000.0,"IncomeLossAttributableToNoncontrollingInterest_2_Q2_USD":700000.0,"IncomeLossAttributableToNoncontrollingInterest_1_Q2_USD":-800000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":123670000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":458540000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":180000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":102000.0,"NetIncomeLoss_2_Q2_USD":-15706000.0,"StockholdersEquity_0_Q2_USD":455549000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":-55000.0,"DeferredOfferingCosts_0_Q2_USD":2700000.0,"ProfitLoss_2_Q2_USD":-15020000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":332672000.0,"Assets_0_Q2_USD":464353000.0,"ShareBasedCompensation_2_Q2_USD":7673000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":5199000.0,"CommonStockSharesAuthorized_0_Q2_shares":150000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":18943000.0,"OperatingIncomeLoss_2_Q2_USD":-15232000.0,"OperatingIncomeLoss_1_Q2_USD":-16604000.0,"ProceedsFromIssuanceInitialPublicOffering_2_Q2_USD":267268000.0,"InvestmentIncomeInterest_2_Q2_USD":222000.0,"InvestmentIncomeInterest_1_Q2_USD":173000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":464353000.0,"DividendsPayableCurrentAndNoncurrent_0_Q2_USD":0.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":7673000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":4165000.0,"DeferredTaxAssetsValuationAllowance_0_Q2_USD":0.0,"OperatingExpenses_2_Q2_USD":34175000.0,"OperatingExpenses_1_Q2_USD":16604000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.37,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.36,"ProfitLoss_1_Q2_USD":-16439000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":-15133000.0,"Ticker":"CGEM","CIK":"1789972","name":"CULLINAN ONCOLOGY, INC.","OfficialName":"Cullinan Oncology Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"494263432.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210810"}]